MetaVia (NASDAQ:MTVA) Announces Earnings Results, Misses Estimates By $0.03 EPS

MetaVia (NASDAQ:MTVA) announced its quarterly earnings data on Wednesday. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03), Zacks reports.

MetaVia Price Performance

MTVA traded down $0.08 during trading on Friday, reaching $1.11. 31,307 shares of the stock were exchanged, compared to its average volume of 217,311. The company has a market capitalization of $5.73 million, a price-to-earnings ratio of -0.13 and a beta of 0.59. MetaVia has a 1 year low of $0.97 and a 1 year high of $19.03. The business’s 50 day moving average price is $1.40 and its two-hundred day moving average price is $4.58.

Institutional Investors Weigh In On MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC acquired a new stake in MetaVia Inc. (NASDAQ:MTVA) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent quarter. Hedge funds and other institutional investors own 1.37% of the company’s stock.

Analyst Ratings Changes

MTVA has been the topic of several research analyst reports. HC Wainwright decreased their target price on shares of MetaVia from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, March 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a research note on Friday, April 24th. Finally, Wall Street Zen raised shares of MetaVia from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $26.50.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.